ANAPTYSBIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 26.23 USD | +1.86% |
|
-0.42% | +22.46% |
| Apr. 16 | Leerink Partners Starts AnaptysBio With Outperform Rating, $47 Price Target | MT |
| Apr. 11 | Wells Fargo Initiates AnaptysBio With Overweight Rating, $56 Price Target | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 18.24M | Sales 2025 * | 26.29M | Capitalization | 703M |
|---|---|---|---|---|---|
| Net income 2024 * | -176M | Net income 2025 * | -194M | EV / Sales 2024 * | 23 x |
| Net cash position 2024 * | 283M | Net cash position 2025 * | 316M | EV / Sales 2025 * | 14.7 x |
| P/E ratio 2024 * |
-4.21
x | P/E ratio 2025 * |
-4.45
x | Employees | 117 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.1% |
More Fundamentals
* Assessed data
More news
Latest transcript on AnaptysBio, Inc.
More recommendations
More press releases
| 1 day | +1.86% | ||
| 1 week | -0.42% | ||
| Current month | +7.76% | ||
| 1 month | +21.83% | ||
| 3 months | +13.99% | ||
| 6 months | +75.92% | ||
| Current year | +22.46% |
1 week
25.17
26.63
1 month
18.4927.02
Current year
18.4927.50
1 year
13.3627.50
3 years
13.3637.89
5 years
10.0079.09
10 years
10.00134.00
| Managers | Title | Age | Since |
|---|---|---|---|
Daniel Faga
CEO | Chief Executive Officer | 44 | 21-11-25 |
Dennis Mulroy
DFI | Director of Finance/CFO | 69 | 20-07-14 |
Paul Lizzul
CTO | Chief Tech/Sci/R&D Officer | 49 | 20-07-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hollings Renton
BRD | Director/Board Member | 77 | 15-06-29 |
Dennis Fenton
BRD | Director/Board Member | 72 | 18-03-04 |
Magda Marquet
BRD | Director/Board Member | 65 | 21-01-17 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.08% | 0 M€ | 0.00% | - | |
| 0.07% | 0 M€ | 0.00% | - | |
| 0.02% | 0 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-09 | 26.23 | +1.86% | 226,338 |
| 24-05-08 | 25.75 | +0.27% | 244,164 |
| 24-05-07 | 25.68 | -0.35% | 320,769 |
| 24-05-06 | 25.77 | -3.05% | 195,199 |
| 24-05-03 | 26.58 | +0.91% | 332,065 |
Delayed Quote Nasdaq, May 09, 2024 at 04:00 pm EDT
More quotes
AnaptysBio, Inc. is a clinical-stage biotechnology company focused on delivering immunology therapeutics. The Company is developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory disease: rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis; and ANB032, its BTLA agonist, in a Phase 2b trial for the treatment of atopic dermatitis. The Company's preclinical immune cell modulator portfolio includes ANB033, an anti-CD122 antagonist antibody, and ANB101, a BDCA2 modulator antibody, for the treatment of autoimmune and inflammatory diseases. In addition, it has developed two cytokine antagonists available for out-licensing: imsidolimab, an anti-IL-36R antagonist, in Phase 3 for the treatment of generalized pustular psoriasis, or GPP, and etokimab, an anti-IL-33 antagonist for the treatment of respiratory disorders that is Phase 2/3 ready.
Calendar
2024-06-11
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
26.23
USD
Average target price
43.67
USD
Spread / Average Target
+66.48%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +22.46% | 717M | |
| +2.97% | 108B | |
| +10.21% | 104B | |
| +1.57% | 22.33B | |
| -12.77% | 22.19B | |
| -7.05% | 18.69B | |
| -37.64% | 17.74B | |
| -6.50% | 17.64B | |
| +6.00% | 14.05B | |
| +37.20% | 12.51B |
- Stock Market
- Equities
- ANAB Stock